Maike Jaworski

Title: Maike Jaworski: Innovator in Antigen Binding Proteins

Introduction

Maike Jaworski is a prominent inventor based in Tuebingen, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins. Her work focuses on innovative solutions for cancer diagnosis and treatment.

Latest Patents

Maike Jaworski holds a patent for "Antigen binding proteins specifically binding PRAME." This invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The patent provides antigen binding proteins that are specific for the tumor-expressed antigen PRAME, which comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins contain the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to the PRAME peptide. These proteins are intended for use in the diagnosis, treatment, and prevention of PRAME-expressing cancerous diseases. Additionally, the patent includes nucleic acids encoding the antigen binding proteins, vectors comprising these nucleic acids, recombinant cells expressing the proteins, and pharmaceutical compositions containing them.

Career Highlights

Maike Jaworski is associated with Immatics Biotechnologies GmbH, where she continues to advance her research in biotechnology. Her innovative work has positioned her as a key figure in the development of targeted cancer therapies.

Collaborations

Maike collaborates with notable colleagues, including Gabriele Pszolla and Martin Hofmann. Their combined expertise contributes to the success of their projects and the advancement of cancer treatment methodologies.

Conclusion

Maike Jaworski's contributions to the field of antigen binding proteins represent a significant advancement in cancer research. Her innovative approach and dedication to improving patient outcomes highlight her importance in the biotechnology sector.